STRS Ohio’s Rein Therapeutics RNTX Stock Holding History

STRS Ohio’s Portfolio RNTX Stock Details RNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-155	Closed	-$25K	–	2193
2018 Q1	$25K	Buy	155 +80	+107%	+$14.3K	﹤0.01%	1807
2017 Q4	$15K	Hold	75	–	–	﹤0.01%	1833
2017 Q3	$20K	Buy	+75	New	+$18.8K	﹤0.01%	1868

Other funds holding RNTX

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

ECM

Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

STRS Ohio's RNTX Position: Q2 2018 in Review

STRS Ohio sold out of Rein Therapeutics (RNTX) in Q2 2018, closing a stake of 155 shares — an estimated $25K sold.

STRS Ohio first reported a position in RNTX in Q3 2017 and held it in 3 quarters. The position peaked at $25K in Q1 2018. 20 funds tracked by Wall St. Rank hold RNTX as of Q2 2018.

STRS Ohio reported no remaining Rein Therapeutics position as of Q2 2018 after selling out during the quarter.
STRS Ohio sold 155 Rein Therapeutics shares in Q2 2018, an estimated $25K.
STRS Ohio first reported a position in Rein Therapeutics in Q3 2017 and held it in 3 quarters.
STRS Ohio's Rein Therapeutics position peaked at $25K in Q1 2018.
20 funds tracked by Wall St. Rank held Rein Therapeutics as of Q2 2018.

Based on STRS Ohio's 13F filing for Q2 2018, filed 6 Aug 2018.